74.62 
0.01(0.01%) 4:02PM EDT
| Prev Close: | 74.63 |
|---|
| Open: | 74.87 |
|---|
| Bid: | 74.36 x 200 |
|---|
| Ask: | 75.95 x 200 |
|---|
| 1y Target Est: | 73.94 |
|---|
| Beta: | 0.55 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 74.45 - 75.73 |
|---|
| 52wk Range: | 51.20 - 75.73 |
|---|
| Volume: | 1,226,169 |
|---|
| Avg Vol (3m): | 1,566,400 |
|---|
| Market Cap: | 183.36B |
|---|
| P/E (ttm): | 18.94 |
|---|
| EPS (ttm): | 3.94 |
|---|
| Div & Yield: | 2.53 (3.40%) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Another Multiple Sclerosis Winner for Biogenat Motley Fool(Wed 4:05PM EDT)
- Regeneron Shareholders Watching Optina Trial Closelyat Seeking Alpha(Wed 3:56PM EDT)
- FDA Designation for Synageva CandidateZacks(Wed 3:50PM EDT)
- Is There Growth Left in Massive Drug Stocks?at Motley Fool(Wed 1:30PM EDT)
- Ariad's Cancer Drug Iclusig Extends The Gleevec Magicat Seeking Alpha(Wed 1:20PM EDT)
- Why Momenta Offers A Unique Opportunity In The Pharmaceutical Industryat Seeking Alpha(Wed 12:56PM EDT)
- Santarus Is a Real Gas!at Motley Fool(Wed 9:06AM EDT)
- Is Merck a Buy at These Prices?at Wall St. Cheat Sheet(Wed 8:43AM EDT)
- Pfizer Stock Checkup for Mayat Motley Fool(Tue, May 21)
- Positive Data on Novartis' AfinitorZacks(Tue, May 21)
- Flush With Cash, Elan Goes on a Buying Spreeat Motley Fool(Tue, May 21)
- Will Influenza A H7N9 Generate Opportunities For Pharma?at Seeking Alpha(Tue, May 21)
- Johnson & Johnson Stock Checkup for Mayat Motley Fool(Tue, May 21)
- Actavis, Warner Chilcott Stocks Rise On Merger Newsat Investor's Business Daily(Mon, May 20)
- Ireland Welcomes Watson Pharmaceuticals, an American Successat TheStreet(Mon, May 20)
Key Statistics
| Forward P/E (1 yr): | 13.79 |
|---|
| P/S (ttm): | 3.17 |
|---|
| Ex-Dividend Date: | 26-Feb-13 |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 4.95 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 1.29 |
|---|
| Mean Recommendation*: | 2.2 |
|---|
| PEG Ratio (5 yr expected): | 2.76 |
|---|
Business Summary
Novartis AG engages in the research, development, manufacture, and marketing of a range of healthcare products worldwide. Its Pharmaceuticals division offers patented prescription medicines in various therapeutic areas, including oncology; primary...
View More